Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

381

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
SchizophreniaBipolar I Disorder
Interventions
DRUG

quetiapine fumarate

Oral dosing, flexible dosing

Trial Locations (48)

Unknown

Research Site, Dothan

Research Site, Scottsdale

Research Site, Cerritos

Research Site, Riverside

Research Site, Sacramento

Research Site, San Diego

Research Site, Denver

Research Site, Altamonte Springs

Research Site, Jacksonville

Research Site, Miami

Research Site, Chicago

Research Site, Oak Brook

Research Site, Newton

Research Site, Overland Park

Research Site, New Orleans

Research Site, Las Vegas

Research Site, Rochester

Research Site, Cincinnati

Research Site, Cleveland

Research Site, Lyndhurst

Research Site, Oklahoma City

Research Site, Philadelphia

Research Site, Memphis

Research Site, Austin

Research Site, Houston

Research Site, San Antonio

Research Site, Richmond

Research Site, Virginia Beach

Research Site, Bellevue

Research Site, Kirkland

Research Site, Milwaukee

Research Site, Lucknow

Research Site, Kuala Lumpur

Research Site, Petaling Jaya

Research Site, Davao City

Research Site, Mandaluyong

Research Site, Manila

Research Site, Quezon City

Research Site, Poznan

Research Site, Torun

Research Site, Moscow

Research Site, Saint Petersburg

Research Site, Belgrade

Research Site, Novi Sad

Research Site, Pretoria

Research Site, Kharkiv

Research Site, Lviv

Research Site, Odesa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY